-
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026
Presentation to Highlight Single-Dose MVA and Continuous Cell-Line MVA Manufacturing Innovations ATLANTA, GA – October 06, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax Highlights Likely Sustained Clade Ib Mpox Transmission in the United States
CDC Reports Changing U.S. Transmission Dynamics Underscore Importance of Continued Surveillance, Vaccine Preparedness and Resilient MVA Vaccine Supply ATLANTA, GA – September 29,…
-
GeoVax Next-Generation MVA Vaccine Demonstrates Durable Single-Dose Protection in Preclinical Models
Study Shows Protection Against Highly Pathogenic Clade I Mpox Virus and Durable CD8+ T-Cell Responses Findings Support GeoVax’s Broader Strategy to Expand the…
-
GeoVax Confirms Bundibugyo Ebola Vaccine Construct
BDBV-Specific Construct Developed Using GeoVax Proprietary Rapid Cloning Technology and Builds on Established Filovirus Vaccine Experience GEO-MVA (Mpox/Smallpox Vaccine) Targeted for Phase 3…
-
GeoVax and CEPI Enter Agreement to Utilize CEPI Centralised Laboratory Network to Support GEO-MVA Phase 3 Trial
Independent Evaluation Supports GEO-MVA Pivotal Phase 3 Program Advances GeoVax’s Strategy to Expand and Diversify MVA Vaccine Supply ATLANTA, GA – September 14,…
-
GeoVax Provides Nasdaq Listing Update and Reaffirms Focus on Advancing Strategic Priorities
ATLANTA, GA – September 10, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies against high-consequence infectious…
-
GeoVax Welcomes Launch of Global Mpox Vaccine Stockpile, Highlights GEO-MVA Readiness to Support Diversified Global Supply
Gavi-funded, ICG-Coordinated Initiative Establishes Long-Term Infrastructure for Timely and Equitable Mpox Vaccine Access During Outbreaks New Stockpile Framework Supports Sustainable Supply and Long-Term…
-
GeoVax Announces a Warrant Inducement Transaction
ATLANTA, GA – August 26, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies, today announced its…
-
GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study Implementation
Selections of CRO and European Clinical Sites Represent Significant Milestones Toward Initiation of the GEO-MVA Immunobridging Study ATLANTA, GA – August 25, 2026…
-
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding Outbreak
Emerging Evidence of Potential Protection From Authorized Ebola Zaire Vaccine Against Bundibugyo Virus Provides Rationale for Evaluating GeoVax’s MVA-Based Ebola Vaccine Candidates ATLANTA,…
-
GeoVax Applauds Clinical Validation of Combination Immunotherapy Strategies
Moderna-Merck Positive Phase 3 Combination Results Reinforce Strategic Rationale for Planned Gedeptin® + KEYTRUDA® Study ATLANTA, GA – August 24, 2026 – GeoVax…
-
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit
Former Georgia Life Sciences Chair Selected for CEO Spotlight and Private Global Health Policy Roundtable with U.S. Rep. Rich McCormick ATLANTA, Ga., August…